ACCESS Newswire·Apr 2, 2026, 9:00 AM ET

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Jaguar Health family company Napo Pharmaceuticals serves as a silver-level sponsor of the April 2-4, 2026 ELITE PED-GI Congress in Abu Dhabi.
Napo supports an ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation for pediatric intestinal failure (IF) patients with microvillus inclusion disease (MVID) or short bowel syndrome (SBS-IF) at Sheikh Khalifa Medical City.
Principal investigator Dr. Mohamad Miqdady reports that study patients have received crofelemer treatment for over one year.
The study demonstrates parenteral support (PS) reductions ranging from 12% to 37% in pediatric IF patients, representing disease progression modification for the lethal MVID condition.
An abstract detailing long-term safety and efficacy of the crofelemer liquid formulation has been submitted for presentation at the ESPGHAN Annual Meeting scheduled for June 2026.
Parenteral support is a life-sustaining treatment associated with significant toxicities including infections, metabolic complications, liver problems, kidney function issues, potential liver failure, and death.
The global market for short bowel syndrome including intestinal failure is estimated to reach approximately $8.0 billion by 2033.
Dr. Miqdady serves as a member of Napo's Scientific Advisory Board.